Safety of biologic agents for the management of rheumatic diseases during pregnancy

Jonathan D. D'Gama, Bonnie L. Bermas

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of reviewTo discuss the current understanding regarding the use of biologic therapeutics in pregnancy.Recent findingsOur understanding of the mechanisms underlying the potential fetal and infant exposure to biologics as well as a growing body of empirical evidence from real world use of biologics in pregnancy have demonstrated that biologics are generally compatible preconception and during pregnancy. Long-term effects of exposure to biologic agents in utero are not known, but will be uncovered in time. Biosimilars, which are becoming more popular, may not always share the same safety profiles as their originators.SummaryBiologics have revolutionized the management of rheumatologic disease and ushered in a new era of clinical remission among patients. These agents, developed and introduced into clinical use at the beginning of the new millennium, are very potent, yet their efficacy in treating disease often in reproductive aged women, raises questions regarding their safety during pregnancy. These therapeutics can cause immunosuppression and can inhibit immunologic circuits that are not only involved in disease pathophysiology but hypothetically could impact the development of the fetal immune system. Reassuringly, biologics, typically antibodies or antibody-based proteins, are introduced to the fetus via the typical route of transplacental antibody transfer, and thus only begin to be transferred in appreciable amounts in the second trimester (after organogenesis). From theoretic and empirical standpoints, biologic use during pregnancy appears well tolerated for fetal development and to not substantially affect infant immune development.

Original languageEnglish (US)
Pages (from-to)184-190
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume36
Issue number3
DOIs
StatePublished - May 1 2024

Keywords

  • antibody
  • antibody-based therapeutic
  • antibody-fusion protein
  • anticytokine inhibitors
  • biologics
  • immunosuppression
  • interleukin-1
  • interleukin-12
  • interleukin-17
  • interleukin-23
  • interleukin-6
  • pregnancy
  • teratogenicity
  • transplacental antibody transfer
  • tumor necrosis factor alpha
  • vertical transmission of immunity

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Safety of biologic agents for the management of rheumatic diseases during pregnancy'. Together they form a unique fingerprint.

Cite this